DaVita HealthCare Partners Inc. shares climbed sharply in morning trade, rising 19.47% to $187.62, after the company released first-quarter 2026 results that materially outperformed analyst projections.
The dialysis provider reported earnings per share of $2.87, well above the consensus forecast of $2.32. Revenue for the quarter totaled $3.42 billion versus the $3.34 billion analysts had expected. Adjusted EBITDA came in at $687.9 million compared with estimates of $610.7 million, representing a 12.6% beat relative to the Street. Management also increased its full-year adjusted EPS guidance, with the midpoint now at $14.65, a 2.4% upward revision.
Investors reacted not only to the magnitude of the beat but also to a set of operational details that underpinned the headline numbers. Revenue per treatment was $417.59, topping Wall Street estimates by $8.30 and showing 4.4% year-on-year growth. Company commentary attributed two-thirds of the $17.45 per-treatment increase to expansion in the core business. Operational efficiency signals included treatments per normalized day rising 40 basis points year-over-year, and management pointed to revenue per treatment growth of 4% driven by rate increases and favorable timing factors.
Adding to the momentum, Deutsche Bank moved quickly after the results with a notable analyst action. The firm upgraded DaVita from Hold to Buy and lifted its price target to $220.00 from $126.00, a substantial upward revision that amplified investor enthusiasm.
Market sentiment ahead of the report had been affected by a significant insider sale. Berkshire Hathaway and Warren Buffett sold about 1,220,376 shares of DaVita common stock on May 1, 2026, for approximately $182.8 million. That transaction had been a headwind to sentiment entering the earnings release but was overtaken by the strength of the quarterly performance.
Competitive dynamics cited on the company’s earnings call also played a role in investor interpretation of the results. Analysts asked executives about the effect of Fresenius clinic closures on DaVita’s market share. Company leadership highlighted the potential to transfer patients from closed Fresenius clinics to DaVita facilities, describing this as a meaningful source of volume upside going forward.
The industry context included other favorable results for healthcare-related providers. Sector peer Encompass Health reported year-on-year revenue growth of 9%, beating analyst expectations and trading higher after its results. That performance contributed to an environment that was broadly constructive for healthcare providers on the day.
Macro conditions were supportive as well, with the broader U.S. equity market posting gains: the S&P 500 rose 0.96%, the Dow Jones increased 1.18%, and the NASDAQ climbed 1.13%. Taken together, the combination of an outsized earnings beat, a raised full-year outlook, a major analyst upgrade with a sharply higher price target, and a favorable sector and market backdrop produced the conditions for DaVita’s exceptional intraday move. The stock reached a new 52-week high on the strength of these catalysts.
Investors noted the quarter’s mix of robust operational performance and disciplined cost management as central to the positive reception. The company’s presentation emphasized improved efficiency metrics and per-treatment revenue growth, which helped drive conviction among market participants and pushed DVA shares markedly higher in early trading.
Summary
DaVita’s Q1 2026 results significantly exceeded expectations across EPS, revenue and adjusted EBITDA, and management raised full-year adjusted EPS guidance. Deutsche Bank upgraded the stock to Buy and lifted its price target sharply higher. Operational metrics such as revenue per treatment and treatments per normalized day showed improvement, and comments on potential patient transfers from Fresenius clinic closures were seen as an additional growth opportunity. The broader market and positive sector results added to the favorable environment for the stock’s nearly 20% gain.
Key points
- DaVita reported EPS of $2.87 versus a $2.32 consensus and revenue of $3.42 billion versus $3.34 billion forecast.
- Adjusted EBITDA was $687.9 million, a 12.6% beat versus the $610.7 million estimate, and full-year adjusted EPS guidance midpoint was raised to $14.65.
- Deutsche Bank upgraded the stock from Hold to Buy and raised its price target to $220.00 from $126.00; revenue per treatment of $417.59 exceeded estimates by $8.30 and grew 4.4% year-over-year.
Risks and uncertainties
- Previous large-scale share sales by Berkshire Hathaway (about 1,220,376 shares on May 1, 2026, for roughly $182.8 million) had weighed on sentiment heading into earnings, highlighting potential sensitivity to insider transactions in the stock.
- While management cited patient-transfer opportunity from Fresenius clinic closures, the realization and scale of that volume upside remain uncertain and were discussed as a potential, not a guaranteed, source of growth.
- Broader market moves and sector dynamics can influence share performance despite strong company-specific results; the supportive macro backdrop on the day aided the rally but may not persist.